NCT07117669View on ClinicalTrials.gov

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Peanut Allergy
Interventions
DRUG

ENP-501

"* Part 1: Participants will receive buccal administrations of ENP-501 daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of ENP-501 daily for 52 weeks following achieving the 2000 µg target dose"

DRUG

Placebo

"* Part 1: Participants will receive buccal administrations of placebo daily for 6-14 weeks~* Part 2: Participants will receive buccal administrations of placebo daily for 52 weeks following achieving the 2000 µg target dose"

Trial Locations (1)

80045

Research Site 001, Aurora

Sponsors

Collaborators (1)

CBCC Global Research
All Listed Sponsors
collaborator

CBCC Global Research

NETWORK

lead

N-Fold, LLC

INDUSTRY

NCT07117669 - Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants | Biotech Hunter | Biotech Hunter